Sign inCreate account

Report workspace tools

NCT04037566UNKNOWNanonymous

A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.

Sponsor

Source record

Xijing Hospital

Phase

Source record

Phase 1

Modality

AI-normalized

cell therapy

Target

AI-normalized

CD19-specific CAR-T cells engineered with CRISPR to eliminate endogenous HPK1.

Indication / condition

AI-normalized

Leukemia Lymphocytic Acute (ALL) in Relapse

Intervention

Source record

XYF19 CAR-T cell, Cyclophosphamide, Fludarabine

Source & freshness

Source record

NCT ID

NCT04037566

Original source

ClinicalTrials.gov

Source last updated

Jul 30, 2019

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04037566

Title

A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.

Sponsor

Xijing Hospital

Status

UNKNOWN

Phase

Phase 1

Condition raw

Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell, CD19 Positive

Condition normalized

Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell, CD19 Positive

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

CD19-specific CAR-T cells engineered with CRISPR to eliminate endogenous HPK1.

Target normalized

CD19-specific CAR-T cells engineered with CRISPR to eliminate endogenous HPK1.

Interventions

XYF19 CAR-T cell, Cyclophosphamide, Fludarabine

Public preview

Source record

The XYF19 CAR-T cell therapy targets CD19, a well-established antigen in B cell malignancies, particularly in relapsed or refractory CD19+ leukemia and lymphoma. The innovative approach of utilizing CRISPR technology to edit endogenous HPK1 may enhance the efficacy and safety profile of CAR-T therapies. The market for CAR-T therapies is expanding, with significant demand for novel treatments in hematological cancers. Competitive analysis indicates that while several CAR-T products exist, the unique genetic modification may provide a differentiated therapeutic option. Diligence should focus on regulatory pathways, potential partnerships with biotech firms, and the evolving landscape of CAR-T therapies in China and globally.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04037566

Status

UNKNOWN

Phase

Phase 1

Sponsor

Xijing Hospital

Executive brief

Investment-Ready Snapshot

The XYF19 CAR-T cell therapy targets CD19, a well-established antigen in B cell malignancies, particularly in relapsed or refractory CD19+ leukemia and lymphoma. The innovative approach of utilizing CRISPR technology to edit endogenous HPK1 may enhance the efficacy and safety profile of CAR-T therapies. The market for CAR-T therapies is expanding, with significant demand for novel treatments in hematological cancers. Competitive analysis indicates that while several CAR-T products exist, the unique genetic modification may provide a differentiated therapeutic option. Diligence should focus on regulatory pathways, potential partnerships with biotech firms, and the evolving landscape of CAR-T therapies in China and globally.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 30, 2019
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04037566

Indication

Leukemia Lymphocytic Acute (ALL) in Relapse

Modality

cell therapy

Target

CD19-specific CAR-T cells engineered with CRISPR to eliminate endogenous HPK1.

Intervention

XYF19 CAR-T cell, Cyclophosphamide, Fludarabine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.